glp 1 agonist drugs for weight loss GLP-1 medications How GLP-1 agonist drugs could

Description

GLP-1 receptor agonist exerts its action through the GLP-1R

#HealthTech #Biotech #GLP1 #Tirzepatide#PharmaNews #Incretins #WeightManagement #DiabetesCare #FutureOfMedicine #Retatrutide #Pharmacology #Endocrinology #Biotechnology #ClinicalTrials #ObesityMedicine #Pharmaceuticals To view or add a comment, sign in Why does Lilly continue to invest in obesity pipelines after Zepbound

GLP-1 gastroparesis affects 4-fold more patients than placebo groups , with non-diabetic users facing 3.33 times higher risk than alternative weight loss treatments Short-acting GLP-1s cause more severe gastric slowing than long-acting versions , delaying emptying by 52 minutes versus 25 minutes respectively Retained gastric contents occur in 13.6% of GLP-1 users versus 2.3% of non-users , creating dangerous aspiration risks during medical procedures Most GLP-1 gastroparesis cases are reversible through tachyphylaxis , with gastric emptying effects diminishing within 4-6 weeks of continuous use Pre-procedural fasting protocols must be extended for GLP-1 users , holding daily medications on procedure day and weekly doses seven days before surgery The condition requires careful differentiation from functional dyspepsia and mechanical obstruction, as proper diagnosis directly impacts treatment outcomes

Exendin-4, by contrast, proved resistant to DPP-4 degradation

FDA has approved Foundayo (orforglipron), developed by Eli Lilly and Company, as the first oral non-peptide GLP-1 receptor agonist for chronic weight management